Pharmerging Market Analysis By Product, By Region {Tier I (China), Tier II (India, Brazil, Russia, South Africa) Tier III (Argentina, Mexico, Poland, Turkey, Indonesia)}, And Segment Forecasts, 2014 - 2025
This report can be delivered to the clients within 48 Business Hours
The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.
According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.
Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.
The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.
Further Key Findings from the Study Suggest:
The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure.
According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.
Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.
The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.
Further Key Findings from the Study Suggest:
- Pharmaceutical segment was the major contributor for the pharmerging market in 2016.
- Pharmaceutical sector also recorded the fastest growth in the pharmerging industry.
- Tier I is driving growth in the pharmerging market.
- India among the Tier II countries is estimated to witness the fastest growth in the pharmerging industry.
- Brazil was recorded as the major contributor for Tier II countries.
- Among Tier III countries, Nigeria and Indonesia are estimated to be driving growth.
- The key players include Sanofi, Pfizer Inc., AstraZeneca, GlaxoSmithKline, F.Hoffmann-La Roche, GE Healthcare, Eli Lilly, Medtronic, Johnson and Johnson, Abbott.
- The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.
CHAPTER 1 EXECUTIVE SUMMARY
1.1 Market Snapshot
CHAPTER 2 RESEARCH METHODOLOGY
2.1 Information procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
CHAPTER 3 PHARMERGING MARKET VARIABLES, TRENDS & SCOPE
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing geriatric population
3.1.1.2 Increasing healthcare expenditure
3.1.1.3 Increasing chronic diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Lack of insurance coverage
3.2 Penetration & growth prospect mapping: Molecule type
3.3 Pharmerging Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
3.5 Country Risk Analysis
3.5.1 Political Risks
3.5.2 Economic Risk
3.5.3 Demographic Risk
CHAPTER 4 PHARMERGING MARKET REGIONAL ESTIMATES & TREND ANALYSIS, BY SERVICE
4.1 Tier I
4.1.1 Reimbursement Policy
4.1.2 Manufacturing outlook
4.1.3 Disease prevalence
4.2 Tier II
4.2.1 India
4.2.1.1 Reimbursement Policy
4.2.1.2 Manufacturing Outlook
4.2.1.3 Disease Prevalence
4.2.2 Russia
4.2.2.1 Reimbursement Policies
4.2.2.2 Disease Prevalence
4.2.3 Brazil
4.2.3.1 Reimbursement Policies
4.2.3.2 Manufacturing Outlook
4.2.3.3 Disease Prevalence
4.2.4 South Africa
4.2.4.1 Reimbursement Policies
4.2.4.2 Healthcare Sector Statistics
4.2.4.3 Disease Prevalence
4.3 Tier III
4.3.1 Argentina
4.3.1.1 Reimbursement Providers
4.3.1.2 Healthcare Availability
4.3.1.3 Disease prevalence
4.3.2 Mexico
4.3.2.1 Healthcare Expenditure Trends
4.3.2.2 Medical Tourism
4.3.2.3 Disease Prevalence
4.3.3 Poland
4.3.3.1 Reimbursement Policy
4.3.3.2 Healthcare Statistics and Disease Burden
4.3.4 Turkey
4.3.4.1 Healthcare Policies
4.3.4.2 Disease Burden
4.3.5 Saudi Arabia
4.3.5.1 Healthcare Policies
4.3.5.2 Disease Burden
4.3.6 Algeria
4.3.6.1 Healthcare Services Outlook
4.3.6.2 Disease Burden
4.3.7 Thailand
4.3.7.1 Healthcare policies
4.3.7.2 Disease Burden
4.3.8 Indonesia
4.3.8.1 Healthcare Policies
4.3.8.2 Disease Burden
4.3.9 Egypt
4.3.9.1 Healthcare Policies
4.3.9.2 Disease Burden
4.3.10 Nigeria
4.3.10.1 Healthcare Policies
4.3.10.2 Disease Burden
4.3.11 Ukraine
4.3.11.1 Healthcare Policies
4.3.11.2 Disease Burden
4.3.12 Pakistan
4.3.12.1 Healthcare Policies
4.3.12.2 Disease Burden
CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 Strategy framework
5.2 Company Profiles
5.2.1 Sanofi
5.2.1.1 Company overview
5.2.1.2 Financial Performance
5.2.1.3 Revenue by National Market
5.2.1.4 Product benchmarking
5.2.1.5 Strategic initiatives
5.2.2 Pfizer Inc.
5.2.2.1 Company overview
5.2.2.2 Financial Performance
5.2.2.3 Revenues by National Market
5.2.2.4 Product benchmarking
5.2.2.5 Strategic initiatives
5.2.3 AstraZeneca
5.2.3.1 Company overview
5.2.3.2 Financial performance
5.2.3.1 Revenues by National Market
5.2.3.2 Product benchmarking
5.2.3.3 Strategic initiatives
5.2.4 GlaxoSmithKline
5.2.4.1 Company overview
5.2.4.2 Financial performance
5.2.4.3 Revenues by National Market
5.2.4.4 Product benchmarking
5.2.4.5 Strategic initiatives
5.2.5 F.Hoffmann-La Roche Ltd
5.2.5.1 Company overview
5.2.5.2 Financial performance
5.2.5.3 Pharmaceutical division Revenues by National Market
5.2.5.4 Diagnostics division Revenues by National Market
5.2.5.5 Product benchmarking
5.2.5.6 Strategic initiatives
5.2.6 GE Healthcare
5.2.6.1 Company overview
5.2.6.2 Financial performance
5.2.6.3 Revenues by National Market
5.2.6.4 Product benchmarking
5.2.6.5 Strategic initiatives
5.2.7 Eli Lilly
5.2.7.1 Company overview
5.2.7.2 Financial performance
5.2.7.3 Revenues by National Market
5.2.7.4 Product benchmarking
5.2.7.5 Strategic initiatives
5.2.8 Medtronic
5.2.8.1 Company overview
5.2.8.2 Financial performance
5.2.8.3 Revenues by National Market
5.2.8.4 Product benchmarking
5.2.8.5 Strategic initiatives
5.2.9 Johnson and Johnson
5.2.9.1 Company overview
5.2.9.2 Financial performance
5.2.9.3 Revenues by National Market
5.2.9.4 Product benchmarking
5.2.9.5 Strategic initiatives
5.2.10 Abbott
5.2.10.1 Company overview
5.2.10.2 Financial performance
5.2.10.3 Revenues by National Market
5.2.10.4 Product benchmarking
5.2.10.5 Strategic initiatives
1.1 Market Snapshot
CHAPTER 2 RESEARCH METHODOLOGY
2.1 Information procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
CHAPTER 3 PHARMERGING MARKET VARIABLES, TRENDS & SCOPE
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing geriatric population
3.1.1.2 Increasing healthcare expenditure
3.1.1.3 Increasing chronic diseases
3.1.2 Market Restraint Analysis
3.1.2.1 Lack of insurance coverage
3.2 Penetration & growth prospect mapping: Molecule type
3.3 Pharmerging Market - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s
3.5 Country Risk Analysis
3.5.1 Political Risks
3.5.2 Economic Risk
3.5.3 Demographic Risk
CHAPTER 4 PHARMERGING MARKET REGIONAL ESTIMATES & TREND ANALYSIS, BY SERVICE
4.1 Tier I
4.1.1 Reimbursement Policy
4.1.2 Manufacturing outlook
4.1.3 Disease prevalence
4.2 Tier II
4.2.1 India
4.2.1.1 Reimbursement Policy
4.2.1.2 Manufacturing Outlook
4.2.1.3 Disease Prevalence
4.2.2 Russia
4.2.2.1 Reimbursement Policies
4.2.2.2 Disease Prevalence
4.2.3 Brazil
4.2.3.1 Reimbursement Policies
4.2.3.2 Manufacturing Outlook
4.2.3.3 Disease Prevalence
4.2.4 South Africa
4.2.4.1 Reimbursement Policies
4.2.4.2 Healthcare Sector Statistics
4.2.4.3 Disease Prevalence
4.3 Tier III
4.3.1 Argentina
4.3.1.1 Reimbursement Providers
4.3.1.2 Healthcare Availability
4.3.1.3 Disease prevalence
4.3.2 Mexico
4.3.2.1 Healthcare Expenditure Trends
4.3.2.2 Medical Tourism
4.3.2.3 Disease Prevalence
4.3.3 Poland
4.3.3.1 Reimbursement Policy
4.3.3.2 Healthcare Statistics and Disease Burden
4.3.4 Turkey
4.3.4.1 Healthcare Policies
4.3.4.2 Disease Burden
4.3.5 Saudi Arabia
4.3.5.1 Healthcare Policies
4.3.5.2 Disease Burden
4.3.6 Algeria
4.3.6.1 Healthcare Services Outlook
4.3.6.2 Disease Burden
4.3.7 Thailand
4.3.7.1 Healthcare policies
4.3.7.2 Disease Burden
4.3.8 Indonesia
4.3.8.1 Healthcare Policies
4.3.8.2 Disease Burden
4.3.9 Egypt
4.3.9.1 Healthcare Policies
4.3.9.2 Disease Burden
4.3.10 Nigeria
4.3.10.1 Healthcare Policies
4.3.10.2 Disease Burden
4.3.11 Ukraine
4.3.11.1 Healthcare Policies
4.3.11.2 Disease Burden
4.3.12 Pakistan
4.3.12.1 Healthcare Policies
4.3.12.2 Disease Burden
CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 Strategy framework
5.2 Company Profiles
5.2.1 Sanofi
5.2.1.1 Company overview
5.2.1.2 Financial Performance
5.2.1.3 Revenue by National Market
5.2.1.4 Product benchmarking
5.2.1.5 Strategic initiatives
5.2.2 Pfizer Inc.
5.2.2.1 Company overview
5.2.2.2 Financial Performance
5.2.2.3 Revenues by National Market
5.2.2.4 Product benchmarking
5.2.2.5 Strategic initiatives
5.2.3 AstraZeneca
5.2.3.1 Company overview
5.2.3.2 Financial performance
5.2.3.1 Revenues by National Market
5.2.3.2 Product benchmarking
5.2.3.3 Strategic initiatives
5.2.4 GlaxoSmithKline
5.2.4.1 Company overview
5.2.4.2 Financial performance
5.2.4.3 Revenues by National Market
5.2.4.4 Product benchmarking
5.2.4.5 Strategic initiatives
5.2.5 F.Hoffmann-La Roche Ltd
5.2.5.1 Company overview
5.2.5.2 Financial performance
5.2.5.3 Pharmaceutical division Revenues by National Market
5.2.5.4 Diagnostics division Revenues by National Market
5.2.5.5 Product benchmarking
5.2.5.6 Strategic initiatives
5.2.6 GE Healthcare
5.2.6.1 Company overview
5.2.6.2 Financial performance
5.2.6.3 Revenues by National Market
5.2.6.4 Product benchmarking
5.2.6.5 Strategic initiatives
5.2.7 Eli Lilly
5.2.7.1 Company overview
5.2.7.2 Financial performance
5.2.7.3 Revenues by National Market
5.2.7.4 Product benchmarking
5.2.7.5 Strategic initiatives
5.2.8 Medtronic
5.2.8.1 Company overview
5.2.8.2 Financial performance
5.2.8.3 Revenues by National Market
5.2.8.4 Product benchmarking
5.2.8.5 Strategic initiatives
5.2.9 Johnson and Johnson
5.2.9.1 Company overview
5.2.9.2 Financial performance
5.2.9.3 Revenues by National Market
5.2.9.4 Product benchmarking
5.2.9.5 Strategic initiatives
5.2.10 Abbott
5.2.10.1 Company overview
5.2.10.2 Financial performance
5.2.10.3 Revenues by National Market
5.2.10.4 Product benchmarking
5.2.10.5 Strategic initiatives
LIST OF TABLES
1. PHARMERGING MARKET BY REGION (2014 - 2025, USD BILLION)
2. PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
3. PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
4. PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
5. TIER 1/CHINA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
6. TIER 1/CHINA PHARMERGING PHARMACEUTICALS MARKET BY EXCLUSIVITY (2014 - 2025, USD BILLION)
7. TIER 1/CHINA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
8. TIER 2 PHARMERGING MARKET BY REGION (2014 - 2025, USD BILLION)
9. TIER 2 PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
10. TIER 2 PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
11. TIER 2 PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
12. BRAZIL PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
13. BRAZIL PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
14. BRAZIL PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
15. INDIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
16. INDIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
17. INDIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
18. RUSSIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
19. RUSSIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
20. RUSSIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
21. SOUTH AFRICA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
22. SOUTH AFRICA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
23. SOUTH AFRICA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
24. TIER 3 PHARMERGING MARKET BY REGION (2014 - 2025, USD BILLION)
25. TIER 3 PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
26. TIER 3 PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
27. TIER 3 PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
28. ARGENTINA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
29. ARGENTINA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
30. ARGENTINA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
31. MEXICO PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
32. MEXICO PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
33. MEXICO PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
34. POLAND PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
35. POLAND PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
36. POLAND PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
37. TURKEY PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
38. TURKEY PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
39. TURKEY PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
40. SAUDI ARABIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
41. SAUDI ARABIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
42. SAUDI ARABIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
43. UKRAINE PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
44. UKRAINE PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
45. UKRAINE PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
46. ALGERIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
47. ALGERIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
48. ALGERIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
49. NIGERIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
50. NIGERIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
51. NIGERIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
52. EGYPT PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
53. EGYPT PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
54. EGYPT PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
55. PAKISTAN PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
56. PAKISTAN PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
57. PAKISTAN PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
58. THAILAND PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
59. THAILAND PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
60. THAILAND PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
61. INDONESIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
62. INDONESIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
63. INDONESIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
1. PHARMERGING MARKET BY REGION (2014 - 2025, USD BILLION)
2. PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
3. PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
4. PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
5. TIER 1/CHINA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
6. TIER 1/CHINA PHARMERGING PHARMACEUTICALS MARKET BY EXCLUSIVITY (2014 - 2025, USD BILLION)
7. TIER 1/CHINA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
8. TIER 2 PHARMERGING MARKET BY REGION (2014 - 2025, USD BILLION)
9. TIER 2 PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
10. TIER 2 PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
11. TIER 2 PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
12. BRAZIL PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
13. BRAZIL PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
14. BRAZIL PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
15. INDIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
16. INDIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
17. INDIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
18. RUSSIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
19. RUSSIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
20. RUSSIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
21. SOUTH AFRICA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
22. SOUTH AFRICA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
23. SOUTH AFRICA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
24. TIER 3 PHARMERGING MARKET BY REGION (2014 - 2025, USD BILLION)
25. TIER 3 PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
26. TIER 3 PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
27. TIER 3 PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
28. ARGENTINA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
29. ARGENTINA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
30. ARGENTINA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
31. MEXICO PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
32. MEXICO PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
33. MEXICO PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
34. POLAND PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
35. POLAND PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
36. POLAND PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
37. TURKEY PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
38. TURKEY PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
39. TURKEY PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
40. SAUDI ARABIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
41. SAUDI ARABIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
42. SAUDI ARABIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
43. UKRAINE PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
44. UKRAINE PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
45. UKRAINE PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
46. ALGERIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
47. ALGERIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
48. ALGERIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
49. NIGERIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
50. NIGERIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
51. NIGERIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
52. EGYPT PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
53. EGYPT PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
54. EGYPT PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
55. PAKISTAN PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
56. PAKISTAN PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
57. PAKISTAN PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
58. THAILAND PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
59. THAILAND PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
60. THAILAND PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
61. INDONESIA PHARMERGING MARKET BY PRODUCT (2014 - 2025, USD BILLION)
62. INDONESIA PHARMERGING PHARMACEUTICALS MARKET BY TYPE (2014 - 2025, USD BILLION)
63. INDONESIA PHARMERGING HEALTHCARE PRODUCTS MARKET BY TYPE (2014 - 2025, USD BILLION)
LIST OF FIGURES
Fig. 1 Market summary (USD Million), 2016
Fig. 2 Market research process
Fig. 3 Information Procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market trends & outlook
Fig. 9 Market segmentation & scope
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 Country Risk Analysis, 2016
Fig. 16 Regional market place: Key takeaways
Fig. 17 Tier I market, 2014 - 2025
Fig. 18 Regional Market Share, 2016
Fig. 19 Tier II market, 2014 - 2025
Fig. 20 Regional Market Share, 2016
Fig. 21 India market, 2014 - 2025
Fig. 22 Disease prevalence
Fig. 23 Russia market, 2014 - 2025
Fig. 24 Brazil market, 2014 - 2025
Fig. 25 South Africa market, 2014 - 2025
Fig. 26 Tier III market, 2014 - 2025
Fig. 27 Regional Market Share, 2016
Fig. 28 Argentina market, 2014 - 2025
Fig. 29 Mexico market, 2014 - 2025
Fig. 30 Poland market, 2014 - 2025
Fig. 31 Turkey market, 2014 - 2025
Fig. 32 Saudi Arabia market, 2014 - 2025
Fig. 33 Algeria market, 2014 - 2025
Fig. 34 Thailand market, 2014 - 2025
Fig. 35 Indonesia market, 2014 - 2025
Fig. 36 Egypt market, 2014 - 2025
Fig. 37 Nigeria market, 2014 - 2025
Fig. 38 Ukraine market, 2014 - 2025
Fig. 39 Pakistan market, 2014 - 2025
Fig. 40 Strategy framework
Fig. 1 Market summary (USD Million), 2016
Fig. 2 Market research process
Fig. 3 Information Procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market trends & outlook
Fig. 9 Market segmentation & scope
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Penetration & growth prospect mapping
Fig. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 Country Risk Analysis, 2016
Fig. 16 Regional market place: Key takeaways
Fig. 17 Tier I market, 2014 - 2025
Fig. 18 Regional Market Share, 2016
Fig. 19 Tier II market, 2014 - 2025
Fig. 20 Regional Market Share, 2016
Fig. 21 India market, 2014 - 2025
Fig. 22 Disease prevalence
Fig. 23 Russia market, 2014 - 2025
Fig. 24 Brazil market, 2014 - 2025
Fig. 25 South Africa market, 2014 - 2025
Fig. 26 Tier III market, 2014 - 2025
Fig. 27 Regional Market Share, 2016
Fig. 28 Argentina market, 2014 - 2025
Fig. 29 Mexico market, 2014 - 2025
Fig. 30 Poland market, 2014 - 2025
Fig. 31 Turkey market, 2014 - 2025
Fig. 32 Saudi Arabia market, 2014 - 2025
Fig. 33 Algeria market, 2014 - 2025
Fig. 34 Thailand market, 2014 - 2025
Fig. 35 Indonesia market, 2014 - 2025
Fig. 36 Egypt market, 2014 - 2025
Fig. 37 Nigeria market, 2014 - 2025
Fig. 38 Ukraine market, 2014 - 2025
Fig. 39 Pakistan market, 2014 - 2025
Fig. 40 Strategy framework
